GLPG Galapagos NV

Galapagos to present at upcoming investor conferences

Galapagos to present at upcoming investor conferences

Mechelen, Belgium; 24 August 2022, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that management will participate in the following upcoming investor conferences: 

  • Citi’s 17th Annual Biopharma Conference. September 8, 2022 in Boston
  • Morgan Stanley 20th Global Healthcare Conference. September 12-14, 2022 in New York
  • Bank of America Merrill Lynch Global Healthcare Conference. September 15, 2022 in London
  • KBC Securities Virtual Life Sciences Conference. September 16, 2022
  • JP Morgan CEO Call Series. September 28, 2022
  • Credit Suisse 31st Annual Healthcare Conference. November 8-10, 2022 in Rancho Palos Verdes, CA
  • Bryan Garnier Virtual Conference on Cell Therapy Innovation. November 14, 2022
  • Jefferies 2022 Global Healthcare Conference. November 16-17, 2022 in London
  • Kepler Cheuvreux Virtual Life Science Days. November 21, 2022
  • Deutsche Bank 2022 Call Series. November 30, 2022



Additional information regarding these events will be available on the investor section of the Galapagos website at .

About Galapagos

Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan. For additional information, please visit or follow us on or .

Contact

Investors:

Sofie Van Gijsel

Head of Investor Relations

Sandra Cauwenberghs

Director Investor Relations

3

Media:

Marieke Vermeersch

Head of Corporate Communication



Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

 

Attachment



EN
24/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Jacob Mekhael
  • Jacob Mekhael

Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE

Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies ...

Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to placebo In the systemic lupus erythematosus study, GLPG3667 delivered numerical improvements on several secondary endpoints compared to placebo but did not achieve statistical significance in primary endpoint analysis The safety profile ...

 PRESS RELEASE

Galapagos maakt topline resultaten bekend van twee fase 3-enabling stu...

Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes GLPG3667 bereikte het primaire eindpunt in de dermatomyositis-studie en toonde een statistisch significant klinisch voordeel en betekenisvolle verbeteringen aan op secundaire eindpunten van ziekteactiviteit in vergelijking met placebo In de studie naar systemische lupus erythematodes leverde GLPG3667 numerieke verbeteringen op voor verschillende secundaire eindpunten in vergelijking met placebo, maar bereikte het geen statisti...

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch